

## Recommendations from York and Scarborough Medicines Commissioning Committee April 2017

Drug name	Indication	Recommendation, rationale and place in therapy	RAG status	Potential full year cost impact
<a href="#">TA433: Apremilast for treating active psoriatic arthritis.</a>		Comments from YFT Rheumatology department indicate that they would plan to use this agent in accordance with NICE guidance and that most physicians would use after a trial of one anti-TNF agent if not contraindicated.	Red	This was approved in March 2017. Patient numbers = low usage ~1 every two months.  Costs = £5610 per patient per year. A PAS scheme is in place. Commissioners should request further details on this from YFT.
<a href="#">TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer</a>		NHS England Commissioned  Cetuximab and panitumumab are recommended as a treatment option for their licensed indications and provided a PAS scheme is in place.	Red and link added to formulary	No cost impact for CCGs. NHS England Commissioner. No significant cost impact is anticipated as a further treatment option and is expected to be similarly priced to other treatment
Nefopam 30mg tablets for pain		Nefopam prescribing has increased substantially in the region. Generic versions of nefopam are almost 6x more expensive than the previous brand (which has been discontinued). There is very little to justify the use of nefopam over other more commonly used non-opioid analgesics.	Black	Cost saving: £54,698 was spent in York CCG on nefopam tablets between January and December 2016.
Fulvestrant – a re-application was received to use fulvestrant for the treatment of oestrogen-receptor positive metastatic or locally advanced breast cancer in postmenopausal women in whom disease progresses or relapses while on, or after, other anti-oestrogen therapy.		It was noted that the new data is in treatment naïve patients and not in the population in which the original application was made. Fulvestrant was not recommended for use in <a href="#">NICE TA 239</a> and this decision still stands as the new evidence wouldn't change the NICE recommendation. NICE will be reviewing use in treatment naïve patients – this is scheduled to be issued in February 2018.	Black	No cost impact as not approved.
York and Scarborough MCC Asthma pathway.		The group approved the asthma pathway following some minor formatting changes.	Green – already in formulary	The pathway is based on BTS guidance and includes products already included

		within the formulary. No further cost impact is expected. A cost effective approach to asthma treatments may offer some cost savings although this is difficult to quantify.
--	--	--